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Cellular and molecular characterization of
multiplex autism in human induced
pluripotent stem cell-derived neurons
Emily M. A. Lewis1†, Kesavan Meganathan1†, Dustin Baldridge2, Paul Gontarz1, Bo Zhang1, Azad Bonni3,
John N. Constantino4 and Kristen L. Kroll1*

Abstract
Background: Autism spectrum disorder (ASD) is a neurodevelopmental disorder with pronounced heritability in
the general population. This is largely attributable to the effects of polygenic susceptibility, with inherited liability
exhibiting distinct sex differences in phenotypic expression. Attempts to model ASD in human cellular systems have
principally involved rare de novo mutations associated with ASD phenocopies. However, by definition, these
models are not representative of polygenic liability, which accounts for the vast share of population-attributable
risk.
Methods: Here, we performed what is, to our knowledge, the first attempt to model multiplex autism using
patient-derived induced pluripotent stem cells (iPSCs) in a family manifesting incremental degrees of phenotypic
expression of inherited liability (absent, intermediate, severe). The family members share an inherited variant of
uncertain significance (VUS) in GPD2, a gene that was previously associated with developmental disability but here
is insufficient by itself to cause ASD. iPSCs from three first-degree relatives and an unrelated control were
differentiated into both cortical excitatory (cExN) and cortical inhibitory (cIN) neurons, and cellular phenotyping and
transcriptomic analysis were conducted.
Results: cExN neurospheres from the two affected individuals were reduced in size, compared to those derived
from unaffected related and unrelated individuals. This reduction was, at least in part, due to increased apoptosis of
cells from affected individuals upon initiation of cExN neural induction. Likewise, cIN neural progenitor cells from
affected individuals exhibited increased apoptosis, compared to both unaffected individuals. Transcriptomic analysis
of both cExN and cIN neural progenitor cells revealed distinct molecular signatures associated with affectation,
including the misregulation of suites of genes associated with neural development, neuronal function, and
behavior, as well as altered expression of ASD risk-associated genes.
Conclusions: We have provided evidence of morphological, physiological, and transcriptomic signatures of
polygenic liability to ASD from an analysis of cellular models derived from a multiplex autism family. ASD is
commonly inherited on the basis of additive genetic liability. Therefore, identifying convergent cellular and
molecular phenotypes resulting from polygenic and monogenic susceptibility may provide a critical bridge for
determining which of the disparate effects of rare highly deleterious mutations might also apply to common
autistic syndromes.
Keywords: Multiplex autism, iPSC modeling, Neurodevelopment, Cortical excitatory neurons, Cortical inhibitory
neurons, Transcriptomics, Gene networks
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Background
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with a complex and poorly understood etiology [1–3]. Behavioral and imaging studies have been
valuable for defining deficits in affected individuals and
characterizing alterations at the level of the brain. However, we are extremely limited in our ability to acquire
or experimentally manipulate human brain tissue from
living patients or post-mortem brain slices. This has
hampered efforts to study cellular and molecular abnormalities that accompany ASD, both during and after
fetal and post-natal development. Notably, both the relative integrity of brain structures in affected individuals
and the diversity of ASD genetics suggest that convergent
mechanisms that contribute to affectation in ASD may
operate at the level of the cell [3, 4]. These may be identifiable in experimental models derived from affected individuals. In particular, ASD appears to frequently involve
abnormal development and/or function of two major classes of neurons in the cerebral cortex, glutamatergic excitatory projection neurons (cExNs) and GABAergic
inhibitory interneurons (cINs) [3, 5, 6]. In vitro
differentiation-based models of these neuronal cell types
can identify cellular and molecular deficits associated with
ASD and provide a tractable platform to screen for
pharmacologic agents that can rescue these deficits.
In recent years, such cellular models of ASD have been
generated, either by deriving induced pluripotent stem
cell lines (iPSCs) from affected individuals or by using
CRISPR/Cas9-based gene editing to engineer ASDassociated mutations into wild-type PSCs [7–19]. Most
of these studies have focused on syndromic forms of
ASD, or on monogenic, de novo cases, where causality is
attributed to the mutation of a single ASD-linked gene
[10, 11, 13–16]. These forms of ASD are attractive for
cellular modeling, as they streamline study design and
reduce many potential confounding variables. Other
studies have included individuals with an unknown genetic cause of ASD, but with subject selection based upon
a shared phenotypic characteristic, such as macrocephaly
[18–20]. Together, these models have been informative,
revealing both cellular and molecular alterations associated with affectation. These include shared and modelspecific disruptions of gene expression in ASD-derived
neurons, frequently involving altered expression of genes
in key developmental signaling pathways, and genes that
control cellular proliferation and growth [7, 8, 13–20]. In
addition, differences were observed in neural precursor
cell (NPC) proliferation and differentiation [9, 19], neurogenesis, [9, 11, 18, 20], synaptogenesis [8, 10, 17, 18], or
functional neuronal activity [7–9, 11, 16, 17]. Altered
expression of ASD genes, in which a mutation is
linked to ASD causation or risk, is also frequently observed [7, 8, 13–16, 18–20].
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These cellular modeling studies have revealed potential contributors to affectation and, in some cases, have
identified targets amenable to pharmacological rescue
in vitro [10, 18]. However, they do not encompass the
range of contributors to ASD burden in the general
population: no single gene mutation accounts for more
than 1% of overall ASD cases with predicted monogenic
causality [21], while the majority of genetic risk appears
to be polygenic or idiopathic [2, 22–28]. Polygenic ASD
risk can involve both common and rare variation in
protein-coding and non-coding regions of the genome,
which may act in a combinatorial manner [2, 27, 29, 30].
Furthermore, ASD exhibits pronounced heritability in
families (estimated at 50–90% [31]), none of which can
be accounted for by de novo (germline) events. Even
within each multiplex ASD family, there is often a considerable range in the extent of affectation among individuals, and in most multiplex autism families, a single
causative gene mutation cannot be identified [31].
While ASD burden in the general population predominantly involves polygenic or idiopathic risk, heritability, and variable affectation [2, 21, 27, 29–31],
these genetically complex forms of the disorder have
been largely neglected in cellular modeling studies.
Therefore, we deemed it important to determine
whether cellular modeling of these complex but
prevalent forms of ASD could also reveal affectationrelated deficits. To test this, we focused on a multiplex ASD family with variable affectation among family members. We generated iPSC lines from three
first degree relatives (a male and a female with differing degrees of affectation and their unaffected
mother), as well as an unrelated unaffected female.
We used these lines to perform differentiation into
both cExN and cIN neural progenitors and/or neurons. Models from the affected individuals exhibited
compromised cellular responses to differentiation cues
and had disrupted gene expression profiles. This included altered expression of many ASD-associated
genes, genes with roles related to behavior, cognition,
and learning, and genes involved in nervous system
development and function, including cell adhesion
molecules and ion channels.
This is, to our knowledge, the first cellular modeling
study of multiplex ASD, including graded affectation
among family members. This work demonstrates that
even genetically complex forms of ASD have discernable
cellular and molecular abnormalities that track with affectation, some of which overlap those identified in prior
modeling of syndromic, monogenic, and de novo forms
of ASD. Therefore, this novel study design highlights the
potential for cellular modeling to identify convergent
hallmarks across the broad diversity and genetic complexity of pathways to affectation.
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Methods
Phenotyping of the multiplex family

The nuclear family consisted of working professional
non-consanguineous parents, whose firstborn child was
a daughter with DSM-5 autism spectrum disorder
(ASD), Level I (requiring support, meeting DSM-5 criteria for Asperger syndrome) who was very high functioning and ultimately attended college, followed by a
pair of monozygotic twin boys with ASD, Level III—one
more fluently verbal than the other but both severely
impaired and requiring very substantial support (see
below)—followed by a third son with very subtle autistic
traits and predominantly affected by attention deficit
hyperactivity disorder, which improved substantially
with stimulant medication treatment. Trio exome sequencing (ES) of one of the twins and his parents revealed a variant of uncertain significance (VUS) in
GPD2, which was inherited by all of the children from
the mother, who is of above-average intelligence with no
dysmorphism and no history of developmental problems.
All pregnancies were uncomplicated, except for the
post-natal hospital course of the twins.
The daughter was born at term with no complications or dysmorphia. Her language and motor development were typical and she was able to read at an
early age. By age five she was reading at a fifth-grade
level. She has been described as talented in writing
and drawing. According to her parents, she exhibited
social oddities from an early age, mainly in communication, and has somewhat intense/restricted interests
in fantasy games. She has strong language abilities,
and currently attends a 4-year college, but at times
uses odd phrases and the rhythm of her speech includes irregular pauses. She has described feeling
alienated and “different”, and was the victim of bullying in middle school, with few close friends. In late
adolescence, she developed major depressive disorder
with moderate severity, which brought her to first
psychiatric contact. She is cognizant of some degree
of social awkwardness, which leads to feelings of anxiety and self-consciousness. The social anxiety inhibits
her from activities such as eating in the cafeteria and
pursuing job opportunities for which she is otherwise
well-qualified. She has a history of becoming emotionally dysregulated and overwhelmed in times of
stress, which has led to self-injurious behaviors. She
has had ongoing struggles with depressive decompensation and suicidal ideation. She has above-average
intelligence but has struggled academically in college
due to depression and anxiety. She is medically
healthy with the exception of supraventricular tachycardia secondary to atrioventricular node reentry,
which was treated with ablation and resulted in subsequent normalization of her electrocardiogram.
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The twin boys were born at 35 weeks, had breathing
problems at birth, and spent 10 days in the newborn intensive care unit. Neither child has any dysmorphic features nor congenital medical abnormalities, and brain
imaging studies were negative. Likewise, neither child
has a history of confirmed seizures; however, there are
concerns for possible absence epilepsy. There is no history of abnormal neurological examination or macro-/
microcephaly. Development of both siblings was delayed,
but neither had appreciable regression. The more severely affected twin (designated as the affected proband,
AP, and from whom the induced pluripotent stem cell
(iPSC) model of severe ASD affectation was acquired)
began to exhibit delays in development by 9 months of
age. He was speaking single words at 14 months and was
ultimately diagnosed with autism at 3.5 years old. Research confirmation of the diagnosis was obtained using
the Autism Diagnostic Observation Schedule. Compared
to his twin brother, he has had more perseverative interests on odd objects. Psychological testing at the age of
nine revealed an IQ of 65 using the Leiter International
Performance Scale. Now in late adolescence, he has the
ability to engage in reciprocal and meaningful verbal exchanges, although his language is often echolalic and repetitive. He is socially motivated and develops superficial
friendships with peers. Functionally, he is able to
complete most self-care, dress himself, prepare food and
feed himself, and count money. He participates in a vocational program at school and is able to complete rudimentary tasks assigned to him. His monozygotic twin
was also diagnosed with ASD at 3.5 years old and is less
severely affected, but still requires significant support.
Selected clinical characteristics of the family members
studied are summarized in Table 1.
Genotyping of the multiplex family

Standard trio ES was performed by the clinical diagnostic laboratory GeneDx for the unaffected mother (UM),
the AP, and the unaffected father. As described by GeneDx, exons were captured and sequenced on an Illumina
platform with at least 100 base pair read length, followed
by alignment to human genome build GRCh37/hg19
and subsequent variant identification. GeneDx’s customdeveloped tool, Xome Analyzer, was used for variant
analysis, as described [32]. This process involves comparing the sequences of each individual to a number of
resources, such as published reference sequences, other
family members, and control individuals, including the
1000 Genomes database, NHLBI Exome Sequencing
Project, ExAC, gnomAD, OMIM, PubMed, and Clinvar.
Variant annotations include evolutionary conservation
scores, results of in silico prediction tools, and references
from the published literature. A phenotype-based approach is also used to generate candidate gene lists. This
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Table 1 Selected clinical characteristics and mutational status of several individuals in the multiplex ASD pedigree
Clinical characteristic

AP

IS

UM

Age of ASD diagnostic confirmation

3.5 years

18 years

N/A

Social responsiveness scale-2

83 T

72 T

56 T (spouse-report)

Depression and anxiety

Yes

Yes

No

Seizure history

No

No

No

Developmental delay

Yes

No

No

Eye contact

Poor

Fair

Good

Repetitive behavior

Yes

No

No

Abnormal sensory sensitivities

Yes

No

No

IQ

65

102 (Raven)

108 (Raven)

Speech delay

Yes

No

No

ASD

Severe

Moderate

No

Intellectual disability

Yes

No

No

Mutation location

GPD2

GPD2

GPD2

chr2:157352686 (hg19) G>A

chr2:157352686 (hg19) G>A

chr2:157352686 (hg19) G>A

p.G78E, c.233G>A

p.G78E, c.233G > A

p.G78E, c.233G>A

information was interpreted by GeneDx experts according to the American College of Medical Genetics and
Genomics Guidelines. ES was performed by The Genome Technology Access Center (GTAC) at Washington
University on the intermediate phenotype sister (IS), and
variant-specific testing was performed by GeneDx on the
trait-affected brother (TB) to confirm the presence of
the identified GPD2 variant.
iPSC generation

iPSC lines were generated by the Genome Engineering
and iPSC Center (GEiC) at Washington University. Biomaterials for reprogramming were only available from
the UM, IS, and AP. Briefly, renal epithelial cells were
isolated and cultured from fresh urine samples and were
reprogrammed using a CytoTune-iPS 2.0 Sendai Reprogramming kit (Thermo Fisher Scientific), following the
manufacturer’s instructions. At least three clonal iPSC
lines were derived for each subject, and one or two of
these clonal lines (clones 1 and 2) were used for all experimentation involving the UM, IS, and AP. The UC
line was previously derived by the GEiC, and one clonal
line was available for use in all experiments involving
this cell line. All clones (clones 1 and 2) used in experiments were assessed for karyotypic abnormalities by the
Washington University School of Medicine Cytogenetics
and Molecular Pathology Laboratory, and were also
characterized for pluripotency by immunocytochemistry
(ICC) and RT-qPCR. Each statistically significant experimental finding reported here was made in experiments
that used two different clonal lines per individual (except
for the UC, where only one clonal line was available),
with at least three independent biological replicate

experiments performed per clonal line. Statistical comparisons were made by one-way ANOVA or unpaired t
test. Documentation of the clone used for each replicate
experiment, the replicates performed, and the statistics
for each finding is detailed in Additional file 1: Table S1.
iPSC maintenance and differentiation

iPSC lines were grown under feeder-free conditions on
Matrigel (Corning) in mTeSR1 (STEMCELL Technologies). cExN and cIN differentiation of iPSCs was performed using previously described protocols [33].
Briefly, for cExN differentiation, iPSCs were dissociated
to single cells with Accutase (Life Technologies) and 40,
000 cells were seeded in V-bottom 96-well non-adherent
plates (Corning). Plates were spun at 200×g for 5 min to
generate embryoid bodies (EBs) and were incubated in
5% CO2 at 37 °C in cExN differentiation medium with
10 μM Y-27632 (Tocris Biosciences). cExN differentiation medium components include Neurobasal-A (Life
Technologies), 1X B-27 supplement (without Vitamin A)
(Life Technologies), 10 μM SB-431542 (Tocris Biosciences), 100 nM LDN-193189 (Tocris Biosciences). On
day four of differentiation, EBs were transferred from Vbottom plates to Poly-L-Ornithine- (20 μg/ml) and laminin- (10 μg/ml) coated plates. Media (without Y-27632)
was replenished every other day, and on day 12, Neural
Rosette Selection reagent (STEMCELL Technologies)
was used to select neural progenitor cells (NPCs) from
within neural rosettes, per the manufacturer’s instructions. cExN NPCs were grown as a monolayer using
cExN differentiation media for up to 15 passages. cIN
differentiation media contained the same components as
cExN differentiation media, while also including 1 μM
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Purmorphamine (Calbiochem) and 2 μM XAV-939
(Tocris Biosciences). EBs were generated as described
for cExNs. At day four of differentiation, the EBs were
transferred to non-adherent plates and were placed on
an orbital shaker (80 rpm) in an incubator with 5% CO2
at 37 °C. The media was replenished every other day
and, at day ten, EBs were transferred to Matrigel- and
laminin- (5 μg/ml) coated plates. Y-27632 was included
in media until day eight of differentiation. On day 12 of
differentiation, NPCs were dissociated with Accutase
and maintained as a monolayer for up to 15 passages.
For both cIN and cExN NPC growth analysis, an equal
number of cells were seeded on Matrigel- and laminin(5 μg/ml) coated plates and total cells were counted 4
days later when the cells reached 70–80% confluence.
For differentiation of cExN NPCs into neurons for
maturation, 40,000 cells per well were seeded in Vbottom 96-well non-adherent plates. Plates were spun at
200×g for 5 min and incubated in 5% CO2 at 37 °C in
maturation medium with Y-27632. Maturation medium
components include Neurobasal-A, 1X B-27 supplement
(without Vitamin A), 200 μM cAMP (Sigma), 200 μM
Ascorbic acid (Sigma), and 20 ng BDNF (PeproTech).
After 2 days, EBs were transferred to Matrigel- and laminin- (5 μg/ml) coated plates and media was replenished
every other day (without Y-27632). On day 12 of neuronal differentiation and maturation, cells were dissociated with Accutase and seeded in an eight-well chamber
for ICC.
For neurosphere size measurement analysis, P values
*P < 0.05, **P < 0.01, ***P < 0.001 were determined by
one-way ANOVA.

For each experiment, approximately one million cells
were pelleted, washed with PBS – Ca2+/Mg2+, resuspended in PBS – Ca2+/Mg2+ and fixed by adding 70%
ice-cold ethanol dropwise while vortexing. Cells were
stained with 10 μg/mL propidium iodide (Sigma) and
200 μg/mL RNase A (Fisher Scientific) in FACS buffer
(PBS – Ca2+/Mg2+, 0.2% BSA, 1 mM EDTA). FACS was
performed on single-cell suspensions and the cell cycle
analysis function of FlowJo was used to analyze cell cycle
composition for each sample, based on propidium iodide
staining to detect DNA content in each cell. P values *P
< 0.05, **P < 0.01, ***P < 0.001 were determined by oneway ANOVA.

Sanger sequencing

RNA-seq and RT-qPCR

DNA was isolated from cell lines using the PureLink
Genomic DNA Kit (Invitrogen). Primers were designed
to amplify a 248 base pair region of GPD2 flanking the
identified point mutation (forward primer: AAGCAG
CAGACTGCATTTCA, reverse primer: CACCATGGCA
CACACTTACC). Sanger sequencing was performed on
this PCR amplified fragment using either the forward or
reverse primer. CodonCode Aligner software was used
to analyze sequencing results.

Total RNA was collected from iPSC-derived day 12
cExN and cIN NPCs using the NucleoSpin RNA II
kit (Takara) per the manufacturer’s instructions. RNA
was quantified using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific), and the integrity of
RNA was confirmed with an Agilent Bioanalyzer 2100
to ensure a RIN value above eight. RNA-sequencing
(RNA-seq) library preparation and Illumina sequencing were performed by the GTAC at Washington
University. Single-end 50 base pair reads were obtained using an Illumina HiSeq 3000 sequencer,
obtaining an average of ~30 million uniquely aligned
reads per sample. For RT-qPCR, 1 μg total RNA was
reverse transcribed using iScript Reverse Transcription
Supermix (Bio-Rad). Equal quantities of cDNA were
used as a template for RT-qPCR, using the Applied
Biosystems Fast Real-Time quantitative PCR system.
RPL30 mRNA levels were used as endogenous controls for normalization. P values *P < 0.05, **P < 0.01,
***P < 0.001 were determined by an unpaired t test.

Immunocytochemistry (ICC) and immunoblotting

For ICC, cells were plated on eight-well chamber slides
coated with Matrigel and laminin (5 μg/mL). After 1 day,
cells were washed once with PBS without calcium and
magnesium (PBS - Ca2+/Mg2+) and fixed in 4% paraformaldehyde for 20 min, followed by washing with PBS +
Ca2+/Mg2+. Cells were blocked with blocking buffer
(10% donkey serum, 1% BSA, and 0.1% TritonX-100 in
PBS + Ca2+/Mg2+) for at least 1 h and incubated with
primary antibodies overnight (Additional file 1: Table

S1) in antibody dilution buffer (1% donkey serum, 1%
BSA, and 0.1% TritonX-100 in PBS + Ca2+/Mg2+). After
overnight incubation, cells were washed three times with
wash buffer (0.1% Triton X-100 in PBS + Ca2+/Mg2+).
Cells were incubated with corresponding secondary antibodies (Additional file 1: Table S1), along with DAPI (1
mg/mL; ThermoFisher Scientific), diluted in antibody dilution buffer for 1 h. Following secondary antibody incubation, cells were washed twice with wash buffer and
once with PBS + Ca2+/Mg2+. Slides were mounted with
Prolong Gold anti-fade agent (Life Technologies). Images were obtained using a spinning-disk confocal
microscope (Quorum) with MetaMorph software and
were processed using ImageJ. For immunoblotting, cell
lysate was extracted and 30 μg of protein was used per
lane. Antibodies used are listed in Additional file 1:
Table S1.
FACS analysis
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Bioinformatics and IPA analyses

RNA-seq data analysis was performed as described in
[33] to curate differentially expressed gene (DEG) lists.
In summary, RNA-seq reads were aligned to the human
genome (assembly hg38) with STAR version 2.5.4b [34].
Gene counts were derived from the number of uniquely
aligned unambiguous reads by Subread:featureCount,
version 1.6.3, with GENCODE gene annotation (V27)
[35, 36]. All gene-level transcript counts were then
imported into the R/Bioconductor package DESeq2 [37].
Genes expressed below a CPM of 1.0 in more than half
the samples were excluded from further analysis. DEG
cutoffs were set at a log2-fold change of > 1.0 and a Benjamini and Hochberg FDR of < 0.05.
To uncover the biological significance of DEGs, network analysis was performed with the data interpretation
tool Ingenuity Pathway Analysis (IPA) (Qiagen). IPA’s
Ingenuity Knowledge Base uses network-eligible DEGs
to generate networks and to define connections between
one and more networks. Based on the number of eligible
DEGs, IPA defines network scores as inversely proportional to the probability of finding the network and defines significant networks (P ≤ 0.001). Within each
network, red symbols indicate upregulated genes and
green symbols indicate downregulated genes, where the
color intensity represents the relative degree of differential expression.
Co-expression and variance analysis

For this correlation analysis, the read counts matrix for
DEGs in either the cIN or cExN samples was log2-CPM
transformed. A similarity matrix for these genes was created by calculating the Euclidian distance among the
genes from the log2-CPM matrix in R. The WGCNA R
package “adjacency.fromSimilarity” function with arguments power=12, type=’signed’ was used to create an
adjacency matrix from the similarity matrix [38]. Hierarchical clustering was performed using the hclust function in R on the distance matrix transformation of the
adjacency matrix using the ward.D2 method. The dendrogram of this gene tree was split into k = 3 clusters
using the cutree function in the stats package of R. The
read counts matrix for all genes in either the cIN or
cExN samples was CPM transformed. Genes expressed
at < 1 CPM in over half of the samples were excluded.
Average CPM among the four sample types was calculated for each gene, and genes with expression ratios of
< 1.25 between the highest and lowest expressed sample
type were excluded from further analysis. The filtered
gene CPM matrix was log2 transformed, and the Pearson correlation matrix for the remaining genes was calculated using the cor function from the stats package in
R. A gene was considered to be correlated to a DEG
cluster if it had a Pearson correlation coefficient > 0.7
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for over half the genes in the DEG cluster. Genes with
expression correlated to a cluster of genes from the
DEG clustering were merged with those genes and fed
into the ToppFun GO analysis of ToppGene [39]. For
each correlated cluster, up to five terms with the most
significant Benjamini and Hochberg FDR values were
retained for each biological process, cellular component,
and molecular function GO terms. The top three pathway and disease terms were also retained for each cluster. To assess the impact of different covariates on
expression, the R/Bioconductor package variancePartition was utilized [40]. The parameters assessed were cell
type (cExN vs. cIN), subject (UC, UM, IS, AP), age
(young vs. old), or sex (male vs. female).

Results
Phenotyping and genotyping of the multiplex family

The multiplex autism spectrum disorder (ASD) pedigree
selected for study (Fig. 1; Table 1) underwent clinical
phenotyping and genotyping (see Methods). From this
pedigree, the individuals selected for iPSC line derivation
and modeling included the affected proband (AP), his
sister, who has an intermediate phenotype (IS), and their
unaffected mother (UM) (indicated in Fig. 1). As described in the Methods, a non-synonymous single nucleotide variant in the GPD2 gene was identified in the
UM and all of the children (chr2:157352686 (hg19)
G>A, NM_001083112.2 c.233G>A, p.G78E). This variant
is not present in the father. The variant is in exon three
of the GPD2 gene, within the region encoding the flavin
adenine dinucleotide (FAD)-binding domain of the
GPD2 protein (Additional file 2: Figure S1A). The GeneDx interpretation of this variant states that it was not
observed in approximately 6500 individuals of European
and African American ancestry in the NHLBI Exome Sequencing Project and that it is evolutionarily conserved.
In addition, in silico analysis predicts that this variant is
probably damaging to the protein structure and
function. Overall, GeneDx designated this as a variant of
uncertain significance (VUS) following the American
College of Medical Genetics criteria. Subsequent
mutation-specific testing and Sanger sequencing identified this same variant in the AP, IS, and UM, while it
was absent in an unrelated, unaffected control (UC)
(Additional file 2: Figure S1B). Given the differential affectation of members of this pedigree carrying this variant, it was apparent that this inherited VUS was
insufficient to cause ASD by itself, but may have contributed to polygenic risk/liability in this family.
Generation of subject-derived iPSC models and directed
differentiation into cortical excitatory neurons

Two clonal iPSC lines were derived from the UM, IS,
and AP, and were characterized in parallel with a single,
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Fig. 1 Pedigree from which samples were derived for this study. GPD2 mutational status (GPD2m: indicates the presence of variant) and degree
of ASD affectation are indicated. Black shading corresponds to the affected proband (AP) and his twin brother, dark grey to the intermediate
phenotype sister (IS), light grey to the trait-affected brother (TB), and white to unaffected family members, including the unaffected mother (UM).
* indicates that renal epithelial cells from these individuals were used to derive multiple clonal iPSC lines.

clonal iPSC line derived from the UC. When grown in
stem cell maintenance media, there were minimal differences observed in the expression of pluripotency
markers between these iPSC lines, as assessed by RTqPCR (Additional file 2: Figure S1C) and immunocytochemistry (ICC) (Additional file 2: Figure S1D). In
addition, no differences in GPD2 protein levels were detected in iPSCs by ICC (Additional file 2: Figure S1D) or
Western blotting (Additional file 2: Figure S1E). All cell
lines used in this study were also shown to be karyotypically normal (Figure S1F). Finally, we used FACS analysis
of propidium iodide (PI)-stained iPSCs to assess cell
cycle progression and detected no observable differences
between these iPSC lines, which had similar percentages
of cells in each stage of the cell cycle (Additional file 2:
Figure S1G-H).
In the cortex, as a result of their abnormal development, imbalances in glutamatergic excitatory neurons
(cExN) and GABAergic inhibitory interneurons (cINs)
are thought to contribute to neurodevelopmental disorders including ASD [3, 5, 41]. We, therefore, differentiated iPSCs derived from the UC, and from three family
members (the UM, IS, and AP), in parallel into either
cExN or cIN neural progenitor cells (NPCs) and/or neurons, to determine if we observed any alterations in the
in vitro development of either or both of these neural

cell types. We performed 12 days of cExN differentiation
(4 days as embryoid bodies (EBs) in V-bottom plates,
followed by 8 days with the EBs plated for twodimensional (2-D) culture; Fig. 2a). At all time points
assessed during this differentiation, the IS and AP lines
generated significantly smaller neurospheres than the
UC and UM. The UM neurospheres were also slightly
smaller than those of the UC (Fig. 2b, c).
To identify whether an increase in apoptosis and/or a
decrease in proliferation could be contributing to these
differences in neurosphere size, we performed FACS
analysis of PI-stained cells at day four of differentiation
and found that the IS and AP neurospheres had a significantly higher fraction of sub-G1 (apoptotic) cells,
compared to neurospheres derived from the UM and
UC lines (< 2 N DNA content; Fig. 2d, e, g). There was a
corresponding decrease in the percentage of cells in the
G1 phase of the cell cycle in the IS and AP neurospheres
(2 N DNA content; Fig. 2d, f–g). However, neurospheres
from all lines had similar percentages of cells in the S
and G2/M phases of the cell cycle, suggesting that their
cell cycle characteristics and rates of progression were
otherwise similar (S phase and 4 N DNA content; Fig. 2d,
g). To determine whether induction of neural differentiation was a stressor that was contributing to this increase
in apoptosis in the IS and AP line-derived neurospheres,
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Fig. 2 Characterization of iPSC lines during differentiation into cExN NPCs. a Differentiation scheme, including timeline and small molecules used.
b, c iPSCs derived from an unrelated, unaffected control (UC), as well as the UM, IS, and AP were differentiated for 12 days to generate cExN
NPCs. Neurosphere size at several time points is shown in (b) and quantified in (c) (mean ± SEM; scale bar = 500 μm; n = 16 biological replicates,
encompassing two different clonal lines from each subject, and one clonal line for the UC). d-g At day four of differentiation, cells were stained
with propidium iodide and FACS analysis of DNA content was performed. d Representative FACS plots. In (e) <2 N (sub-G1) and (f) 2 N (G1) cells
are quantified, with values shown for each replicate. g shows mean values for all cell cycle stages for each cell line (mean ± SEM; n = 3 or more
biological replicates for each subject, encompassing two different clonal lines from each subject, and one clonal line for the UC). h-i iPSCs were
cultured in either neural induction media or in mTeSR stem cell media, and EB size was analyzed at day four of differentiation. Representative
images are shown in (h) (scale bar = 500 μm), with quantification in (i) (mean ± SEM; n = 3 or more biological replicates for each subject,
encompassing two different clonal lines from each subject, and one clonal line for the UC). P values *P < 0.05, **P < 0.01, ***P < 0.001 were
determined by one-way ANOVA and all other pairwise comparisons had a non-significant P value (P ≥ 0.05). Red and black data points denote
experiments performed with clone 1 or with clone 2, respectively

we compared sphere size after culturing spheres from
each line either in stem cell maintenance media (mTeSR)
or in neural induction media. In general, sphere size was
larger for all cell lines when kept in mTeSR media rather
than neural induction media, while the differences in
sphere size for the IS and AP versus the UC and UM was
much less pronounced in mTeSR, relative to differences
seen under neural induction conditions (Fig. 2h, i). These
data suggest that, by comparison with the UC and UM,
the IS and AP lines have a slightly elevated propensity to
undergo apoptosis upon dissociation and sphere formation, while this is exacerbated by induction of neural
differentiation.
We next maintained these four lines as NPCs after
neural rosette selection at day 12 and then subjected them
to PI staining and FACS analysis (Additional file 2: Figure
S2A). Unlike the results from earlier time points, the cExN
NPCs showed little difference in cell cycle across the four
lines (Additional file 2: Figure S2B-C), nor in the rate of
growth or apoptosis over the course of culture for 4 days
(Additional file 2: Figure S2D). However, morphological
analysis by bright-field imaging indicated a possible adhesion defect in the IS NPCs, as indicated by uneven growth
on the cell culture plate surface (Additional file 2: Figure
S2E). At the NPC stage, GPD2 protein levels remained
similar across the four lines, as was shown for iPSCs (Additional file 2: Figure S2F).
Finally, to determine if the NPCs derived from the affected individuals exhibited an altered capacity to differentiate into cExN neurons, NPCs from the four lines were
further differentiated for 12 days as shown (Additional file
2: Figure S3A) and subjected to ICC. No apparent differences between the four lines were observed in the expression of NPC markers (PAX6, NESTIN, and SOX1) or
markers of immature (TUJ1) and mature cExN neurons
(VGLUT, MAP2) (Additional file 2: Figure S3B). Furthermore, there were no observable differences between the
lines in the fraction of cells expressing Ki-67, a marker of
cell proliferation, or cleaved Caspase-3, a marker of apoptosis (Additional file 2: Figure S3B).

Differentiation of subject-derived iPSCs into cortical
interneuron progenitors

We also characterized cellular phenotypes of these four
lines during differentiation into cIN NPCs, to define any
differences between the development of this neural cell
type in lines derived from affected and unaffected individuals. The differentiation scheme to produce cIN
NPCs is outlined in Fig. 3a. On day five of differentiation
in this scheme, neurospheres derived from the IS line
were smaller than those of the UM. Conversely, the AP
line-derived neurospheres were slightly larger than the
UM line neurospheres (Additional file 2: Figure S4).
After dissociation on day 12 of differentiation, we
assessed the cell cycle of the cIN NPCs using FACS of
PI-stained cells (Fig. 3b–e). The IS and AP cIN NPCs
had an increased sub-G1 cell population, compared to
the UC and UM NPCs, an indication of increased apoptosis in the cells from the affected individuals (Fig. 3c).
Correspondingly, there was a decrease in the proportion
of cells in the G1 phase of the cell cycle (Fig. 3d). However, no differences were observed in frequencies of cells
in the S and G2/M phases of the cell cycle between lines,
suggesting that these lines had similar proliferation rates
(Fig. 3b, e). This result was supported by analysis of
NPC cell counts after 4 days of growth, which revealed a
significant reduction in the number of AP NPCs, as well
as a slight reduction in the number of IS NPCs, compared to the UM NPCs (Fig. 3f). These reductions in
NPC number may have resulted from the increased
NPC apoptosis detected in our PI FACS analysis. The
AP NPCs also exhibited altered morphology that could
indicate impaired adhesion capacity relative to the control UM/UC lines, which could also have contributed to
the reduction in the number of AP NPCs persisting in
the culture after 4 days of growth (Fig. 3g).
Transcriptomic differences in neural progenitor cells
derived from affected individuals versus controls

To investigate which classes of genes could be differentially expressed in neural cells from the affected
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Fig. 3 Characterization of iPSC-derived cIN NPCs. a Differentiation scheme, including timeline and small molecules used. b-d After 12 days of
differentiation, cIN NPCs were stained with propidium iodide and analyzed by FACS for DNA content. (b) Representative FACS plots. In C and D,
respectively, < 2 N (sub-G1) and 2 N (G1) cells were quantified, with values shown for each replicate (n = 3 or more biological replicates from
each of two clonal lines for each subject, and one clonal line for the UC). e Mean percentages of cells in each cell cycle stage are shown (n = 3
or more biological replicates from each of two clonal lines for each subject). f-g cIN NPCs were plated in equal numbers for each sample and
counted after four days of culture. Data are quantified in (f) and representative images are shown in (g) (n = 3 or more biological replicates from
each of two clonal lines for each subject, and one clonal line for the UC). P values *P < 0.05, **P < 0.01, ***P < 0.001 were determined by oneway ANOVA and all other pairwise comparisons had a non-significant P value (P ≥ 0.05). Red and black data points denote experiments
performed with clone 1 or with clone 2, respectively

individuals, by comparison with the unaffected controls,
we performed RNA-seq analysis on both cExN and cIN
NPCs on day 12 of differentiation for all four subjectderived lines. Four biological replicates were analyzed
for each sample type and were clustered by principal
component analysis (PCA) of processed reads (Additional file 2: Figure S5A). We defined genes that were
significantly differentially expressed genes (DEGs) in
pairwise comparisons of these four sample types for either cExN or cIN NPCs, selecting DEGs with a log2-fold
difference between sample types of > 1 and a Benjamini
and Hochberg FDR of < 0.05 (Additional file 3: Table
S2). In a within-family comparison of the UM, IS, and
AP samples, greater numbers of DEGs were obtained in
the cIN NPC pairwise comparisons versus the numbers
of DEGs obtained for cExN NPC pairwise comparisons
(Additional file 2: Figure S5B-C). These data indicate
that the cIN samples from the affected individuals
(IS/AP) exhibit more transcriptomic differences from
the UM control than the affected individual-derived
cExN samples.
We focused first on identifying classes of genes that
were differentially expressed in NPCs derived from the affected individuals, by comparison with unaffected controls. To do this, we defined the subset of DEGs that were
similarly expressed in samples from both affected individuals (AP/IS) but that differed in expression by comparison
with the unaffected mother (UM) sample. Relative expression is also shown for the UC, for a full cross-sample comparison. Four hundred fifty-two and 437 DEGs for the
cExN and cIN NPC samples met these criteria, respectively. Hierarchical clustering and visualization of the relative expression of these DEGs across the four sample
types are shown for the cExN NPCs (Fig. 4a, Additional
file 4: Table S3). We next used the Ingenuity Pathway
Analysis (IPA) to assess the potential biological significance of these genes. For the 452 DEGs in the cExN NPCs
described above, the most significant function- and
disease-related gene ontology (GO) terms included ‘behavior’, ‘neurological disease’, and ‘embryonic development’ (Fig. 4b). Network analysis using IPA revealed
several interesting networks of DEGs related to these GO
terms, including networks related to ‘locomotion’ (from
DEGs within the ‘behavior’ GO term) and ‘behavior and

developmental disorder’ (Fig. 4c, d). Within the ‘locomotion’ network, most genes were upregulated in the affected
individuals compared to the controls, including genes relating to neural adhesion and ion channels (Fig. 4c and
Additional file 5: Table S4). Genes with known roles in
NPCs or neurons, as well as stress-related genes were
present in the larger ‘behavior and developmental disorder’ network (Fig. 4d and Additional file 5: Table S4).
Interestingly, another network comprising genes from the
GO term ‘neurological disease’ is related to ‘inflammation
of central nervous system’ (Additional file 2: Figure S6A
and Additional file 5: Table S4).
IPA analysis of the cIN DEGs also revealed several interesting classes of genes that were differentially expressed
between the affected participants and unaffected control
NPC-derived samples. Hierarchical clustering and
visualization of the relative expression of DEGs across the
four sample types for the cIN NPCs are shown in Fig. 4e
(Additional file 4: Table S3). The top GO terms included
‘developmental disorder’, ‘behavior’, ‘nervous system development and function’, ‘psychological disorders’, and
‘neurological disease’ (Fig. 4f). Within the term ‘behavior’,
a network that includes ‘learning’-, ‘cognition’-, and ‘behavior’-related genes was identified (Fig. 4g, Additional file
5: Table S4). The network related to the GO term ‘psychological disorder’ includes genes related to ‘anxiety disorders’, ‘mood disorders’, and ‘depressive disorder’ (Fig. 4h).
The ‘nervous system development and function’ network
includes genes involved in the ‘quantity of neurons’ and
‘quantity of synapse’, as well as cell adhesion genes (Additional file 2: Figure S6B and Additional file 5: Table S4).
Finally, a ‘neurological’ network included a number of
genes also present in the other networks (Additional file 2:
Figure S6C). We further assessed these affectation-linked
DEGs by gene co-expression analysis and hierarchical
clustering, as described in the methods (Additional file 2:
Figure S7). Gene ontology analysis of co-expressed gene
clusters identified neuron-related (e.g. neuron projection,
axon, synapse) and neurological disease-related terms (e.g.
mental depression, autistic disorder) as top GO terms
(Additional file 6: Table S5). Taken together, this analysis
of DEGs in both cExN and cIN NPCs shows evidence of
altered expression of a number of neurological and psychological disease-relevant gene classes in the AP- and IS-
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Fig. 4 Transcriptomic analysis of genes with differential expression in affected subject-derived NPCs, relative to unaffected controls. a Hierarchical
clustering of RNA-seq data from the cExN NPCs identified differentially expressed genes (DEGs) with shared expression in the AP and IS that
differed from that in the UM. Relative expression is also shown for the UC, for a full cross-sample comparison (P < 0.05, fold-change > 2; n = 4
biological replicates from one clonal line for each subject, and one clonal line for the UC). b-d Ingenuity Pathway Analysis (IPA) of these cExN
NPC DEGs defined disease- and function-associated gene ontology (GO) terms and identified gene networks associated with the (c) ‘behavior’
and (d) ‘behavior and developmental disorder’ GO terms. e Hierarchical clustering of RNA-seq data for the cIN NPCs identified DEGs with shared
expression in the AP and IS, that differed from that in the UM. Relative expression is also shown for the UC, for a full cross-sample comparison (P
< 0.05, fold-change > 2; n = 4 biological replicates from one clonal line for each subject, and one clonal line for the UC). f-h IPA analysis of these
cIN NPC DEGs defined (f) disease- and function-associated GO terms and identified gene networks associated with (g) ‘behavior’ and (h)
‘psychological disorder’. Within each network, red symbols indicate upregulated genes and green symbols indicate downregulated genes, while
color intensity indicates the relative degree of differential expression

derived lines, relative to lines derived from the UM and/or
UC.

gene expression changes, therefore, correlate with and
may contribute to, the severity of affectation in the AP.

Within-family comparison identifies a transcriptome
signature specific to neural progenitor cells derived from
the ASD-affected proband

Comparison of differentially expressed genes with ASDassociated genes and validation

As differences in genetic background can confound differential gene expression analysis [42], we also performed a pairwise, within-family data comparison of
DEGs that distinguish the UM-, IS-, and AP-derived
samples, focusing on DEGs specific to the AP that could
contribute to the greater degree of affectation observed.
Using pairwise comparisons of DEGs, we defined 190
genes which were uniquely differentially expressed in
cExN NPCs from the AP (Fig. 5a). The top GO terms
associated with these AP-specific DEGs included ‘psychological disorders’, ‘behavior’, ‘nervous system development and function’, ‘developmental disorder’, and
‘neurological disease’ terms (Fig. 5b). Within the ‘behavior’ term, network analysis showed genes related to
‘memory’ and ‘learning’ to be dysregulated (Fig. 5c and
Additional file 5: Table S4). Within the ‘nervous system
development and function’ term, a network of dysregulated genes related to ‘differentiation of neurons’ was
identified (Fig. 5d, Additional file 5: Table S4).
A similar analysis was performed on the cIN samples,
revealing 384 DEGs unique to the AP samples in the
within-family comparison (Fig. 5e). IPA analysis identified
classes of DEGs related to the GO terms ‘psychological
disorders’, ‘developmental disorder’, ‘neurological disease’,
‘behavior’, and ‘nervous system development and function’
(Fig. 5f). Within the ‘behavior’ disease term, a network of
genes related to ‘behavior’ and ‘cognition’ was identified
(Fig. 5g and Additional file 5: Table S4). Within the ‘nervous system development and function’ term, a network
of genes related to ‘development of neurons’ and ‘synaptic
transmission’ had altered expression in the AP versus the
IS/UM-derived samples (Fig. 5h and Additional file 5:
Table S4). Together, this analysis identified AP-unique
DEGs in both cExN and cIN NPCs, many of which are
broadly related to neural development, as well as to specific aspects of ASD, such as behavioral alterations. These

The Simons Foundation Autism Research Initiative
(SFARI) [43] maintains a database of genes that are mutated to cause or that contribute to ASD risk. We compared our DEGs to these ASD-related genes, to assess
whether their dysregulated expression could contribute
to affectation in these individuals. Of the 584 unique
DEGs in the cExN differentiation scheme that were either specific to the AP (Fig. 5a) or that had similar expression in the AP and IS that differed from that seen in
the UM (Fig. 4a), 30 (5.1%) were SFARI ASD genes (Fig.
6a; Additional file 6: Table S5). For the corresponding
cIN NPC comparison, 48 of 692 unique DEGs (6.9%)
were ASD genes in the SFARI Gene database (Fig. 6b;
Additional file 6: Table S5). Based upon the 1019 genes
present in the SFARI Gene database [43] and the total of
27,731 genes with > 0.1 RPKM average expression across
all cExN and cIN samples, the number of AP- and ISspecific DEGs that are ASD genes is significantly greater
than would be expected by chance (hypergeometric distribution, P = 3.67 × 10−3 and 3.49 × 10−7 for cExN and
cIN data, respectively). A subset of these are associated
with syndromic ASD (NTNG1, ALDH1A3, DMD, EBF3,
PRODH, and RNF135) and/or are linked with ASD with
the highest confidence (SFARI gene scores 1–2: KATNAL2, MYT1L, CACNA2D3, GRIA1, SCN9A, and
CNTN4). Comparison with the 465 genes in the Geisinger Developmental Brain Disorder Gene Database
also revealed recurrent association of some of these
genes with ASD and/or intellectual disability, but infrequent association with other neurological disorders
(Additional file 6: Table S5) [44]. Interestingly, only one
(for cExN) or none (for cIN) of the DEGs overlapped
with high-confidence genes unique to adult-onset
psychiatric disorders (e.g., not also associated with neurodevelopmental disorders) identified in the PsyGeNET
database (Additional file 6: Table S5) [45, 46]. Therefore,
it is possible that misregulated expression and
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Fig. 5 Within-family analysis of transcriptomic signatures specific to the affected proband-derived samples. a Venn diagram for the cExN NPCs,
showing the DEGs from pairwise comparisons of different samples, including numbers of overlapping DEGs. The blue shaded portion of the Venn
diagram indicates DEGs unique to the AP, not shared by the IS or UM. b-d Ingenuity Pathway Analysis (IPA) of the AP-unique DEGs in cExN NPCs
defined (b) class and function-associated GO terms and identified gene networks associated with (c) ‘behavior’ and (d) ‘nervous system development
and function’. e-h IPA analysis of the AP-unique DEGs in cIN NPCs determined (f) class and function-associated GO terms and identified gene networks
associated with (g) ‘behavior’ and (h) ‘nervous system development and function’. Within each network, red symbols indicate upregulated genes and
green symbols indicate downregulated genes, where the color intensity represents the relative degree of differential expression

consequently the function of ASD genes contributed to
the disruption of neural development and/or continues
to contribute to altered neurological function in the IS
and AP.
We validated the differential expression of a subset of
the DEGs described above by RT-qPCR analysis, isolating RNA from NPCs derived from the second set of
iPSC clones that differed from those used for the RNAseq experiments. Expression changes of DEGs selected
from the cExN NPC RNA-seq data (Fig. 7a) were robustly recapitulated in these experiments (Fig. 7b).
Genes from the ‘behavior and developmental disorder’,
from other identified networks, and genes involved in
neurodevelopment were evaluated (Additional file 5:
Table S4). We also derived cIN NPC RNA from the second set of iPSC clones and validated the corresponding
RNA-seq data for a subset of the DEGs (Fig. 7c). Differential expression was assessed for SFARI ASD genes
[43], and for genes encoding transcription factors, ion
channels, and cell adhesion molecules (Fig. 7d, e and
Additional file 5: Table S4). In addition, we validated a
subset of DEGs in cINs which also had differential expression in cExN NPCs (Fig. 7e).
Differential gene expression in iPSC disease modeling
studies involving female iPSC lines can be confounded
by erosion of X-inactivation, including alteration of sex
chromosome-linked gene expression [47–50]. Therefore,
we also assessed XIST expression levels, as an indicator
of potential X-erosion in our female lines. We observed
that XIST RNA expression was reduced in the UC but
not in either clonal line derived from the UM or IS, evidence of potential X-erosion in the UC line (Additional
file 2: Figure S8A-B). However, as few of our DEGs are
X-linked (Additional file 4: Table S3), this does not appear to be a major contributor to the differential gene
expression identified in this study. Finally, we performed
variancePartition analysis on these RNA-seq data to
quantify contributions of multiple sources of variation to
the differential gene expression obtained. The cell type
(cExN or cIN) or subject from whom the sample was derived were the main contributors to differential gene expression, while the age and sex of the subject were only
minor contributors to the total variance observed in
both cExN and cIN RNA-seq datasets (Additional file 2:
Figure S8C). Together, these analyses revealed that

relative to unaffected individuals, samples from affected
individuals exhibited altered expression of classes of
genes involved in behavior, learning, cognition, mood
disorders, and neurodevelopment, including perturbed
ASD gene expression, suggesting that these differences
could contribute to aberrant neural development or
function in the affected individuals.

Discussion
In recent years, the genetic structure of autism spectrum
disorder (ASD) risk in the general population has been
clarified. This work has confirmed that while, in some
cases, deleterious, single gene variants are significant
contributors to ASD, the vast proportion of population
attributable risk is polygenic [2, 51]. Furthermore, this
risk is highly heritable, and individuals within a multiplex family typically exhibit variable degrees of affectation [31]. Here, we modeled cellular and molecular
correlates of ASD within one such multiplex family, performing cortical neural differentiation of iPSCs derived
from several family members with differential affectation. In this family, both polygenic liability and a shared
variant of uncertain significance (VUS) may contribute
to risk. In cells derived from the affected individuals, we
identified compromised responses to differentiation cues
and altered gene expression profiles during iPSC differentiation into cortical excitatory (cExN) and inhibitory
(cINs) neurons, compared to related and unrelated unaffected controls. This work demonstrates that iPSCbased modeling can be used to characterize these more
genetically complex but prevalent forms of ASD, in
addition to modeling simplex and monogenic forms,
which have been the focus of most studies to date.
Moreover, these data provide information on physiologic
and transcriptomic signatures of multiplex autism, with
which cellular models derived from other families and
other combinations of inherited susceptibility factors can
be compared in future work.
Our phenotypic analysis of these four iPSC-based
models of cortical neural development included assays
conducted in the stem cells, during neural specification,
in the proliferating NPCs, and during neuronal differentiation. During cExN NPC specification and during cIN
NPC propagation, models from both affected individuals
exhibited elevated fractions of cells with sub-G1 DNA
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Fig. 6 Hierarchical clustering of DEGs that are also ASD genes in the SFARI autism gene database. a Relative gene expression for the cExN NPC
samples. b Relative gene expression for the cIN NPC samples. Data from four biological replicates from one clonal line are shown for each sample type
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Fig. 7 Validation of DEGs of interest identified from RNA-seq experiments by RT-qPCR. Genes tested are related to behavior and developmental
disorders, adhesion, and ion channels. a, b Comparison of relative gene expression in cExN NPCs for the UM, IS, and AP by (a) RNA-seq and (b) RT-qPCR,
including expression analysis of genes related to ‘behavior and developmental disorders’. c-e Comparison of gene expression between the UM, IS, and
AP for the cIN NPCs by (c) RNA-seq and by (d, e) RT-qPCR, both for genes that were (d) differentially expressed only in the cIN NPCs, and (e) for genes
that were differentially expressed in both cExN and cIN NPCs. P values *P < 0.05, **P < 0.01, ***P < 0.001 were determined by an unpaired t test and all
other pairwise comparisons had a non-signficant P value (P ≥ 0.05). RT-qPCR data shown includes n = 3 or more biological replicates from one clonal
line per subject, where samples were generated for each subject by using a second clonal iPSC line that differed from the line used for RNA-seq analysis

content, relative to control-derived models. These data
suggest that models derived from the affected individuals
are less resistant to stressors, such as induction of differentiation, with these stressors increasing the propensity
for cells to undergo apoptosis. While the molecular trigger for the induction of apoptosis here is unclear, expression of stress and apoptosis-related genes, such as
CHCHD2, ANXA1, and SPATA18 are dysregulated in
these models [52–56]. These findings are reminiscent of
some observations made in prior work, in which schizophrenia subject-derived iPSCs exhibited reduced neurosphere size [57] and increased apoptosis was observed in
Williams-Syndrome iPSC-derived NPCs [58]. Interestingly, few studies report cellular alterations observed
prior to the NPC stage, often focusing predominantly on
phenotypes seen in NPCs and mature neurons [7–19].
While this may reflect a lack of earlier phenotypic
changes in some models, our findings highlight the importance of tracking neurodevelopmental alterations
from their earliest onset. A recent report underscores
the value of using cellular modeling approaches that aim
to recapitulate some aspects of in vivo neurodevelopment [20]. This study found that direct conversion of
iPSCs into neurons masked ASD-associated cellular phenotypes, which were observable during the directed differentiation of iPSCs [20].
In our study, transcriptomic analysis of neural progenitor cells revealed dysregulated expression in affected
individuals compared to controls of gene networks related to behavior, psychological disorders, and neuronal
development and disease. Genes encoding transcription
factors were among the neurodevelopment-related genes
with reduced expression in both affected individuals. For
example, ARX is required for normal telencephalic development and is associated with syndromic autism and
other neurodevelopmental disorders [59], while EMX1
and FOXB1 also play important roles in neural development [60–62]. Behavioral misregulation is a key trait of
ASD, and gene networks related to the GO term ‘behavior’ exhibited dysregulated expression in both affected
individuals. Genes in these networks include COMT,
ADCYAP1, CNR1, HTR2C, GRIK2, and RGS4, all of
which are implicated in behavior-related phenotypes in
humans and/or mice [63–71]. ASD genes were also dysregulated in these affected individuals, relative to controls.

Mutation of these genes in other individuals is implicated
in autism risk or causation. These include adhesion-related
genes (PCDHA1, PCHDHA6, PCDHGA11, PCDH8,
PCDH9, PCDH10 [72–76], KIRREL3 [77], CNTN3, CNTN4
[78], CNTNAP4 [79], and THBS1 [80]), receptor and channel genes (CACNA2D3 and SCN9A [81], GRIK2 and GRIK3
[82–85], KCNJ2 [86, 87], and GRIA1 [88, 89]), and genes
associated with central nervous system development and
axon guidance (ERBB4 [90, 91], NTNG1 [92], TSHZ3 [93],
EBF3 [94], MYT1L [95, 96], and ANXA1 [54–56]). Altered
expression of ASD-associated genes has also been observed
in cellular models derived from affected individuals in other
studies [8, 13–16, 19, 97]. Therefore, these findings suggest
that misregulated expression of suites of ASD-associated
genes may contribute to risk or affectation, and may do so
by altering neurodevelopment and/or neuronal function in
these affected individuals.
A unique aspect of this study is the use of iPSC-based
directed differentiation into both cExNs and cINs, enabling us to identify neural cell-type-specific alterations associated with affectation. Although DEGs identified in
affected individuals in both neural cell types were associated with many similar functions and diseases (e.g., behavior), the specific DEGs obtained often varied by cell
type. For example, cIN DEGs included many more ASDassociated genes and protocadherin genes, the latter of
which control neuronal migration, axonal growth, and
synapse formation [74, 75]. Human post-mortem cortical tissue from individuals with ASD has been shown
to exhibit disrupted expression of cIN-associated genes,
evidence that this cell type may commonly be disrupted
in affected individuals in vivo [98]. These findings suggest that extending cellular modeling studies to multiple
disease-relevant neuronal cell types, including cINs, may
reveal additional neurodevelopmental disruptions related
to affectation.
To define cellular and molecular perturbations commonly related to affectation, we compared our findings
to other studies that modeled ASD by directed differentiation of iPSCs into cExNs. We identified subsets of
overlapping DEGs in comparisons with studies involving
idiopathic autism cases vs. controls (26 shared DEGs
[7]), syndromic ASD involving macrocephaly (31 shared
DEGs [19]), and modeling of mutation of the syndromic
ASD gene CHD8 (32 shared DEGs [13]) (Additional file
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7: Table S6). Data for such comparisons is limited at
present because iPSC-based models have been generated
for a relatively small number of individuals and mutations, and these almost exclusively characterize cExNs or
cerebral organoids [7, 13, 18, 19].
The multiplex pedigree studied here was subjected to
clinical exome sequencing, as it was hypothesized that a
single, shared, genetic contributor might mediate autism
risk and differential phenotypic expression in this family.
In this sequencing analysis, a thread of shared genetic liability among all children was a VUS in the ASD- and
ID-associated gene, GPD2 [99–101], which was inherited
from their mother. However, there is variable ASD expressivity among these individuals, ranging from absent,
to intermediate, to severe. In addition, both males and
females in the pedigree are variably affected, indicating
the presence of other significant contributors to variation in severity of affectation within this family. This
observation is consistent with recent evidence that genetic liability for ASD is prevalently polygenic, and that,
even in multiplex pedigrees where a significant monogenic contributor has been identified, additional polygenic risk can contribute to affectation [51]. Moreover,
this multiplex family was prototypic in reflecting the
most severe form of affectation occurring in a male.
We hypothesized that it might be possible to identify
graded cellular phenotypes that correlated with the level
of severity of phenotypic expression. In general, we instead observed many cellular and molecular alterations
that were shared by the cellular models derived from the
affected individuals, while not being observed in those
derived from the unaffected individuals. However, we
did define some proband-specific DEGs, not present in
the less severely affected sister, many of which relate to
behavior and nervous system development. A subset of
these DEGs had graded expression, exhibiting intermediate expression levels in the intermediate phenotype sister, between her unaffected mother and her severely
affected brother. These findings suggest that both the
degree of dysregulation of expression and the number
and identity of DEGs within these networks may contribute to the level of affectation. While further experimentation might reveal additional graded phenotypes,
particularly in mature neurons, ex vivo cellular modeling
cannot recapitulate many aspects of fetal and post-natal
neurodevelopment that may have been perturbed to
contribute to the graded affectation observed in these
individuals.

Limitations
This work highlights several considerations for ongoing
scientific efforts to model this complex but prevalent
form of ASD in future studies. First, since the unique
characteristics of any multiplex ASD pedigree present
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challenges for cellular modeling, it is important to control for sex and variation in affectation in subject and
family selection, study design, and analysis. Related to this
point is the importance of modeling affected females in
such studies. Most ASD cellular modeling to date has
been restricted to affected males [7–10, 13, 14, 16, 18, 19],
given the increased prevalence of ASD among males, and
the fact that constraint to a single sex simplifies some
modeling considerations. In particular, sex chromosome
dosage effects do not need to be accounted for in male
cells, while female-derived iPSC models cannot currently
recapitulate the process of random X-chromosome inactivation that occurs in developing somatic tissues, including
the brain [102, 103]. However, the transcriptomic differences that we observed here were not driven by sex
chromosome-linked gene expression: very few DEGs in
any potential pairwise sample comparison (whether between same or opposite sex models) were sex
chromosome-linked and/or potential contributors to sexbiased gene expression in the human brain [104, 105].
Therefore, this work supports the feasibility of identifying
DEGs associated with affectation by cellular model crosscomparisons, even when these models are derived from
both female and male subjects.
Furthermore, studying both unaffected and affected
male and female individuals within a multiplex family, as
in this pedigree, necessitates consideration of how the
so-called female protective effect may contribute to affectation [106–108]. Multiplex ASD families often exhibit differences in phenotypic expression of additive
genetic liability, some of which appear to be related to
sex. While the most affected individual in this family is
male, we cannot fully differentiate the contributors to
variable phenotypic expression of ASD in this pedigree,
which also includes an unaffected male and affected and
unaffected females. However, this experimental system
could identify affectation-linked phenotypes that may
have involved a sex-based contributor, since both the
cellular and behavioral phenotypes of the females studied here differed from that of the affected male. Future
studies in strategically-selected samples such as these
provide an opportunity to assess how sex influences
phenotypic expression of ASD genetic liability; if such
mechanisms exist at the level of the cell, this approach
may yield insights into sex-specific interventions.
Another consideration for iPSC-based modeling of
ASD is genetic background, which can be a confounding
variable for cross-comparisons [42]. In this pedigree,
ASD risk was polygenic, such that it was not possible to
engineer a correction of a single genome variant to
create pairs of isogenic mutant versus wild-type iPSC
lines with an identical genetic background for study. In
such cases, modeling of first degree relatives may serve
as the best control, and modeling of multiple related
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individuals with varying affectation provides additional
opportunities for identifying potential contributors to
these differences in affectation. Including unrelated controls and performing comparisons with other studies can
further highlight which phenotypic and transcriptomic
alterations track with affectation, even by comparison
with models derived from individuals with an unrelated
genetic background.

Conclusions
In summary, this work used robust schemes for differentiation of cortical neurons from iPSCs to model cellular
and molecular signatures associated with multiplex ASD
in a family reflecting varying degrees of affectation. Even
in this prevalent, complex form of ASD, involving heritability, polygenic etiology, and variable affectation, we
could identify affectation-linked cellular and molecular
alterations of neurodevelopment, some of which overlapped those defined in other iPSC-based studies of
monogenic, syndromic, and de novo ASD. As more cellular models of ASD are characterized, these data can be
harnessed in the search for convergent and divergent
contributors to impairment across the genetically complex and multi-factorial pathways that give rise to ASD.
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